Dendreon
|
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that harness the immune system to fight cancer. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer. On January 12, 2007, the FDA accepted BLA filing and assigned Priority Review status for Provenge.
(Source: 10-K)
More from Zoominfo » |
Dendreon's Provenge gets FDA review date
Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.
From AP via Yahoo! News - 1 day ago
Dendreon's Provenge gets FDA review date
Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1. The drug is aimed at treating prostate cancer. It works as a vaccine to stimulate the... Dendreon - Food and Drug Administration - Cancer - Prostate cancer - Provenge
From San Francisco Chronicle - 1 day ago
Dendreon's Provenge gets FDA review date
Biotechnology company Dendreon said Friday that the Food and Drug Administration will make a regulatory decision on the potential prostate...
From Seattle Times - 1 day ago
More news from Yahoo! News
|
|
|
